Most founders dream of raising millions. Few survive the 153 “no’s” it takes to get there.

Behind every biotech breakthrough lies exhaustion — late-night calls, failed rounds, and investors who walk away at the finish line.

What separates the ones who make it isn’t luck or timing — it’s resilience built into process.

In this episode, Jason Foster, CEO of Ori Biotech, shares how he transformed relentless rejection into a billion-dollar trajectory. From rebuilding cell-therapy manufacturing to leading global teams through economic storms, Jason reveals how founders can systematize grit, master storytelling, and survive when everything seems to fall apart.

You’ll learn how to navigate fundraising winters, why leadership begins with self-care, and how to build companies that endure long after the hype fades.
 If you’ve ever doubted your path as a builder, this conversation will remind you that resilience is not a trait — it’s a practice.

💡 What You’ll Learn in This Episode

1️⃣ The real reason most founders fail long before capital runs out
2️⃣ How to turn rejection into momentum using process and habit
3️⃣ Why storytelling is the most underrated skill in biotech leadership
4️⃣ How resilience and self-care directly drive performance and valuation
5️⃣ The mindset that separates enduring companies from short-term success

👤 About Jason Foster

Jason Foster is the CEO of Ori Biotech, a leading innovator transforming cell and gene therapy manufacturing. With 20+ years in global health, he has raised over $140M, led companies through IPO-level growth, and serves as a mentor and investor to emerging founders in life sciences. His mission: make advanced therapies accessible to every patient, everywhere.

💬 Quotes That Might Change How You Think

(00:14:09) “There are cures for cancer today, but patients can’t reach them — access must change.” 
(00:37:22) “The science is extraordinary — but if we can’t make it at scale, it means nothing.” 
(01:22:17) “Purpose, not money, drives talent to transform lives through innovation.” 
(01:46:17) “Fundraising is a war of attrition — constant rejection tests your resilience more than your idea.” 
(02:02:16) “You only have to get up one more time than you’re knocked down.” 

🧭 Timestamps to Explore

(00:02:00) Embracing Hard Challenges — How Biotech Founders Build Resilience That Lasts
(00:13:40) The Unacceptable Truth: Cures Exist, Yet Patients Still Can’t Access Them
(00:26:23) Navigating Cultures — What European and American Biotech Leaders Can Learn From Each Other
(00:32:52) Why Great Science Isn’t Enough Without Commercial Viability
(00:39:19) Revolutionizing Cell Therapy Manufacturing — The Seven-Day Bottleneck Explained
(00:50:11) Automation and Digitization — Unlocking Scalable Patient Access in Cell and Gene Therapy
(01:09:30) Rethinking Capacity Utilization — Making Regional Biotech Manufacturing Centers Work
(01:14:27) Mass Personalization — The Future Delivery Model for Advanced Therapies
(01:23:00) Purpose-Driven Talent — The Secret to Retaining Top Biotech Performers
(01:32:18) Fundraisin

Send us a text

Join Christian Soschner for expert coaching.
50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now.

Support the show

Join the Podcast Newsletter: Link

Imagine waking up to find your company’s most valuable IP leaked—not by hackers, but by the very AI tools you trusted.
This isn’t a distant scenario; it’s happening inside pharma and biotech right now.
And the cost isn’t just financial—it’s patient lives, broken trust, and an industry on the edge of losing credibility. 

In this episode, Kat Kozyrytska shares how leaders can act before invisible risks become catastrophic. From her personal journey in post-Soviet Ukraine to building frameworks in global biotech, Kat reveals why “yesterday problems” with AI demand urgent attention today.

You’ll learn how data privacy failures propagate quietly, why embedding organizational values into AI is essential, and how collaboration across companies can safeguard innovation and accelerate therapies. 

The future of biotech won’t be secured by hype or speed—but by trust, ethics, and the courage to act before it’s too late. 

🎧 What You’ll Learn in This Episode
1️⃣ Why “yesterday problems” with AI in pharma are already costing billions
2️⃣ How data privacy failures silently erode trust, IP, and patient safety
3️⃣ The difference between collaboration and competition in biotech innovation
4️⃣ Why embedding organizational values into AI is no longer optional
5️⃣ The future of drug discovery, clinical trials, and manufacturing in an AI-first world 

👤 About Kat Kozyrytska
Kat Kozyrytska is the Founder of the Cell Therapy Manufacturability Program and a global thought leader at the intersection of biotech and AI. With roots in Ukraine and a career spanning MIT, Stanford, Thermo Fisher, Sartorius, and global biotech startups, she bridges technical depth with ethical foresight. 

💬 Quotes That Might Change How You Think
(00:14:50) "AI can amplify good or bad behaviors — the choice is ours."
(00:38:14) "Discovering dark personalities is like learning Santa isn’t real — traumatic, but suddenly everything makes sense."
(01:03:26) "AI speaks with absolute confidence, but confidence is not the same as truth."
(01:20:22) "AI gives us a rare chance to embed ethics and values into innovation."
(01:57:01) "If personalized therapies work better, we have an ethical duty to deliver them." 

🧭 Timestamps to Explore
(00:05:16) From Math to Medicine – Kat’s unexpected path from equations to biotech leadership
(00:09:38) Inside a Nobel Lab – How neuroscience breakthroughs shaped her ethical lens
(00:12:27) Shadow AI – Why biotech leaders can’t wait to govern hidden systems
(00:23:03) Data Sharing Paradox – Collaboration vs confidentiality in pharma innovation
(00:31:31) Neurobiology of Manipulation – How dark personalities exploit human trust
(00:41:18) Hidden Privacy Risks – What your everyday data footprint really reveals
(00:52:17) Soviet Control vs American Individualism – Lessons for AI governance today
(00:57:30) The Danger of One Answer – Why converging on a single AI truth is risky
(01:02:51) Confidence ≠ Expertise – Rethinking how we trust AI in science
(01:18:16) Embedding Core Values – How leaders can align AI with human ethics
(01:51:28) Breaking Down Silos – Th

Send us a text

Join Christian Soschner for expert coaching.
50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now.

Support the show

Join the Podcast Newsletter: Link

Most founders obsess over products. Jensen Huang built a $3 trillion company by obsessing over inevitabilities. 

This episode unpacks The NVIDIA Way by Tae Kim—the definitive account of how NVIDIA went from near-death startup to the world’s most valuable chipmaker. More than a history, it’s a manual for founders and VCs navigating the messy, high-stakes stretch between Series A and IPO. 

But this isn’t just about NVIDIA. 

It’s about you—if you’re scaling in deep tech, where survival depends less on genius inventions and more on how you engineer resilience, culture, and urgency into your system. 

I walk you through 7 scaling lessons that matter now—from why pain is a founder’s greatest teacher to how vision and culture become moats no competitor can copy. Each principle is grounded in NVIDIA’s story, translated into today’s market reality, and wrapped with coaching prompts you can act on this week. 

Key Takeaways: 

• Pain Builds Resilience: Intelligence helps, but scars compound faster.
• Reputation Is Currency: Your first product isn’t a chip or an app—it’s trust.
• Defy the Innovator’s Dilemma: Don’t chase quarters—build inevitabilities.
• Lead with Context: Replace bottlenecks with clarity and extreme ownership.
• Sell the Vision: Markets follow narratives, not features.
• Culture Outruns Capital: Execution habits compound longer than cash.
• Urgency Wins: Complacency kills more companies than competition.

Timestamps:
(00:00) Why This Episode Matters
(02:18) The Big Idea of The NVIDIA Way by Tae Kim
(04:36) Who is Tae Kim?
(08:15) Lesson #1: Pain and Suffering Are the Recipe for Greatness
(12:35) Lesson #2: Your Reputation Is Your Currency
(17:05) Lesson #3: The Innovator’s Dilemma Will Come for You
(21:45) Lesson #4: Lead With Context, Not Control
(25:18) Lesson #5: Don’t Just Sell the Product—Sell the Vision
(30:00) Lesson #6: Culture Outruns Capital—and the Competition
(34:32) Lesson #7: Build Urgency Into the System
(38:30) Key Takeaways—3x Reading + 25 Years in Public Markets, VC, and Scaling Deep Tech
(41:24) Reflection

Why Listen:

• Learn how NVIDIA survived near-death and built inevitabilities that defined AI.
• Get 7 leadership and culture principles designed for Series A–IPO scale-ups.
• See how to evaluate companies not by products, but by the systems that endure.
• Upgrade your founder or investor lens with actionable coaching questions.

Found this valuable? Like, share, and follow.
 Every signal grows the show—and helps bring you more playbooks from the world’s most resilient companies.
 
 🎙️ - Beginner's Mind. Top 10% global. #1 deep tech podcast. 200+ episodes.
 

Send us a text

Join Christian Soschner for expert coaching.
50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now.

Support the show

Join the Podcast Newsletter: Link

How do you succeed in a business where being wrong is the norm?

Marc Penkala has lived both sides of the table: as an entrepreneur who built, sold, and failed with companies—and now as a venture capitalist running his own fund. What makes his story different is the radical honesty about what actually drives success in venture: failure, timing, and taking risks that look stupid at first.

This Spark20 episode distills Marc’s hard-earned lessons into a 20-minute masterclass for founders, investors, and policymakers navigating uncertainty.

What you’ll learn

• Why timing, not brilliance, often decides who wins.
• Why failure is the ultimate credibility builder for investors.
• How European founders hold themselves back—and what mindset shift is overdue.
• Why down markets are the best time to build companies.
• How the “stupidest ideas” sometimes create the biggest outliers.

Timestamps & Quotes

📌 (00:00:38) Entrepreneur → VC
“My route into venture capital felt like a paid executive MBA… I built, I sold, I bankrupted, and then I joined the so-called evil side to truly understand investors.”

📌 (00:03:31) Failure as Fuel
“Failure is the bigger success… many of my failures turned into the best things that ever happened.”

📌 (00:05:32) Credibility Through Scars
“If I had never built a company, how could I authentically tell a founder I can help them?”

📌 (00:07:29) Wrong = Right in Venture
“As a VC, you’re more often wrong than right. And strangely, the more you’re wrong, the higher your actual output.”

📌 (00:10:38) When Tourists Arrive, Leave
“The moment angels and LPs with no clue flood the market, you literally have to stop investing. That’s when the tourists arrive.”

📌 (00:12:22) Outliers Make the Portfolio
“One angel had ten bets—two of them gorillas and Tier. Didn’t matter what else he had—the outliers alone defined him.”

📌 (00:13:02) Europe vs. US Mindset
“US startups think in billions. European startups think in millions. That mentality shift is everything.”

📌 (00:15:02) Stupid Ideas Win
“If everyone agrees it’s a great deal, don’t do it. The best investments sound like the stupidest idea at first.”

📌 (00:17:42) Why Down Markets Build Giants
“In down markets, founders get humble, go back to fundamentals, and focus on capital efficiency. That’s why the best companies come from downturns.”

This isn’t just a highlight reel—it’s a reminder that in venture capital and entrepreneurship, the rules are upside down. Being wrong isn’t a weakness—it’s proof you’re taking the swings that matter.

👉 Listen now, and share it with someone who needs to think bigger.

🎙️ With over 200 interviews, panels, and livestreams, Beginner’s Mind ranks in the Top 10% globally—and is recognized as the leading deep tech podcast for

Send us a text

Support the show

Join the Podcast Newsletter: Link

Here’s the harsh truth: If your business model can’t survive a spreadsheet, it won’t survive the market.

Every year, ambitious founders pour months into product, pitch, and brand—yet the single biggest reason startups die isn’t funding, it’s flawed modeling.

What are the four variables investors use to spot winners before anyone else?

In this episode, investor and hands-on builder Alex Oppenheimer (Founder & GP at Verissimo Ventures, ex-Facebook IPO, ex-NEA, Monday.com advisor) reveals why most startup advice misses the point—and how the best founders reverse-engineer success long before a single euro is raised.

🎧 Watch now to learn:
1️⃣ The business model simulation Alex uses to kill (or greenlight) a deal in under an hour
2️⃣ The one thing top VCs always ask founders—but almost nobody prepares for
3️⃣ Why a founder’s “calling” is more important than their credentials
4️⃣ How to avoid the European trap of ignoring leverage and failing to scale
5️⃣ The subtle mindset shift that separates bold investors from the herd—and how to apply it to your own company

👤 About Alex Oppenheimer
Stanford-trained engineer, ex-Morgan Stanley tech banker, NEA Series A investor, Monday.com operator, and now founder of Verissimo Ventures—a fund that bets on weird tech and next-gen software models in Israel, the US, and Europe.

💬 Quotes That Might Change How You Think:
(00:59:00) “If I don't build this, nobody else will—that’s the founder’s true calling.”
(01:12:45) “How can you know what data to collect if you don’t know the model?”
(01:22:36) “The real job of an investor is helping great founders not mess it up.”

🧭 Timestamps to Explore:
(00:04:00) Quitting Corporate Venture—The Decision That Changed Everything
(00:11:50) What Business Modeling Is (and Isn’t)
(00:18:30) Trusting the Founder Over the Deck
(00:24:40) Venture Capital and the Power of Naivete
(00:34:03) Inside the Facebook IPO Data Room
(00:44:38) Lessons from Betting on Outliers
(00:49:48) Leaving NEA to Build Israel’s Next Scaleups
(01:02:32) From Frustration to Founding a Venture Fund
(01:10:57) Why Business Modeling Remains a Blind Spot
(01:14:09) Redefining Value Investing in Venture Capital
(01:15:50) Decoding Value with Core Variables
(01:22:36) Helping Founders Avoid Unnecessary Pitfalls Early 

🔔 Like what you hear?
Follow the show and share this episode with one builder, founder, or investor you respect.
Every share helps us bring new industry leaders and sharper insights straight to you.
Subscribe now—your next breakthrough could be one episode away.

🎙️ Beginner’s Mind
Top 10% globally. The leading podcast for VCs, operators, and anyone obsessed with building what comes next.

Send us a text

Join Christian Soschner for expert coaching.
50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now.

Support the show

Join the Podcast Newsletter: Link

Why do Europe’s brightest founders still feel forced to leave for Silicon Valley—no matter how much money or talent we pour into the region?
 Every year, ambitious startups across Europe and CEE struggle to scale—not for lack of ideas, but because of invisible barriers that keep global success out of reach.

Is it really just about capital—or is there a deeper mindset and playbook that only a handful of founders ever discover?

In this episode, venture insider Enis Hulli (General Partner at e2vc, investor in 40+ startups, 3 unicorns, and builder of bridges from Istanbul to the Bay) pulls back the curtain on the real reasons US-based startups keep winning—and how founders from Turkey, Eastern Europe, and beyond can finally turn the tables.

🎧 Watch now to learn:
1️⃣ The “power law” that decides which founders build generational companies—and why most never see it coming
2️⃣ Why relationships, not pitch decks, determine who actually gets funded—and how to break through if you don’t have the right connections
3️⃣ How emotional resilience and founder mindset shape the fate of entire regions—not just individuals
4️⃣ The little-known risks of playing the European “safe game”—and how to engineer luck for outsized results
5️⃣ Tactical lessons on team building, brand, and why your anti-portfolio (the deals you missed) might matter even more than your winners

👤 About Enis Hulli
Enis is General Partner at e2vc, a leading early-stage venture fund focused on scaling tech startups from Emerging Europe to global markets. With investments in 40+ companies (including three unicorns), he’s spent his career helping founders unlock the path from local player to world-class leader.

💬 Quotes That Might Shift Your Thinking:
(01:30:44) “I don’t think we’ll see founders choosing Europe over the US in our…”
(01:34:37) “There are twenty different ways to kill a reputation on any side of the…”
(01:38:31) “To avoid complacency, I surround myself with people who make me feel like I…”

🧭 Timestamps to Explore:
(00:16:58) How the Bay Area’s Talent Network Effect Became Unstoppable
(00:20:48) Work-Life Balance vs. Blitzscaling—What It Really Takes to Go from Zero to One
(00:25:43) Why Founders Trump Pitch Decks Every Time
(00:30:38) The Perils of Planning for an Exit Too Soon
(00:34:34) The Three Qualities Every VC Looks For—And Why Mindset Still Wins
(00:40:30) How IPO Markets Shape (and Break) Venture Capital
(00:43:52) Fundraising Mistakes That Kill FOMO and Crush Deals
(01:12:58) Why Bay Area Mindset Still Outpaces Europe’s Best
(01:30:44) The Real Reason Europe Loses Its Unicorns
(01:34:37) Reputation, Relationships, and the Hidden Dangers of VC Control
(01:38:31) How Top Investors Avoid Complacency and Stay Hungry

🔔 Follow the show and leave a review. Every follow, like, and share brings new global voices, industry leaders, and sharpest insights straight to you.

🎙️ Beginner’s Mind ranks in the Top 10% globally—and is recognized as the

Send us a text

Join Christian Soschner for expert coaching.
50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now.

Support the show

Join the Podcast Newsletter: Link

Still trying to optimize your health with guesswork and generic advice?
Most people settle for “one-size-fits-all” supplements and hope for the best-missing out on the breakthroughs that only real data and personalization can offer.
In a world flooded with empty promises, few realize how quickly tailored, science-backed solutions can transform energy, focus, and longevity.

Enter Vadim Fedotov—ex-pro athlete, CEO, and co-founder of Bioniq, the health tech company bringing truly personalized care to the world’s top leaders, innovators, and athletes.

In this eye-opening conversation, Vadim reveals why your biology is as unique as your fingerprint—and why the future belongs to those who personalize, measure, and adapt.
Discover the systems, mindsets, and science behind optimizing human potential—without wasting time, money, or hope on outdated approaches.

🎧 Watch now to explore:
1️⃣ The fatal flaw in “one-size-fits-all” wellness—and how personalization is rewriting the rules
2️⃣ How AI, data, and regular feedback loops empower you to outpace your peers—at work, in health, and in life
3️⃣ Lessons from elite sports: why discipline, team dynamics, and feedback matter in business
4️⃣ The “feedback loop” secret that’s changing the supplement industry forever
5️⃣ Vadim’s vision for a future where your fridge, wearable, and AI coach work together to help you thrive

👤 About Vadim Fedotov
Vadim is the co-founder and CEO of Bioniq, former CEO at Groupon, and a former professional basketball player with the German National Team and Buffalo Bulls. Driven by his passion for health optimization, he’s building a global, interdisciplinary network of thought leaders to put cutting-edge, personalized care within everyone’s reach.

💬 Quotes That Might Shift Your Thinking:
(00:08:27) "Personalized health isn't a trend; it's the future of wellness."

(00:15:54) "There is no single right diet, exercise, or routine—every body truly needs something different."

(00:44:11) "Personalization in health is not a luxury anymore; it’s quickly becoming a necessity."

(01:06:26) "You only fail when you give up—resilience defines success."

(01:23:21) "Seventy percent of your health is determined by nutrition, not pharmaceuticals or medicine."

🧭 Timestamps to Explore:
(00:03:32) Why Visionary Leaders and Families Move to Dubai
(00:08:27) Personalizing Health Revolution How Data-Driven Wellness Changes Everything
(00:09:27) Health as the New Wealth Post-Covid Insights
(00:15:52) Busting Health Myths There’s No One-Size-Fits-All
(00:18:28) Data Over Opinion Navigating Health Complexity
(00:21:03) Olympic Research Sparks Personalized Health Innovation
(00:23:51) When Obvious Solutions Don’t Exist—The Birth of Bioniq
(00:25:40) When a "Dumb Idea" Becomes a Massive Opportunity
(00:31:01) Setting Personal Health Goals With AI and Data
(00:34:40) Real-World Feedback Loops Cut Through Wellness Hype
(00:40:07) Data-Driven Breakthroughs That Save Lives
(00:44:11) Why Health Personalization Is Now a Necessity
(00:54:31) Leadership, Discipline, and Lessons from El

Send us a text

Join Christian Soschner for expert coaching.
50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now.

Support the show

Join the Podcast Newsletter: Link

How do you lead at the cutting edge of health, data, and AI—while staying deeply human?

Angeli Möller has led global data science teams across pharma giants, co-founded one of Europe’s most ambitious AI alliances, and now builds high-performance biotech strategies with precision. But what truly sets her apart isn’t just her technical fluency—it’s her clarity, courage, and care in how she builds teams, solves problems, and pushes the boundaries of innovation.

In this episode, Angeli opens up about the quiet frustrations that fuel her mission, the invisible cost of ignoring innovation, and the principles that guide her client work today. Whether you’re an investor, founder, or policymaker, her journey will reshape how you think about leadership, AI, and what truly moves the needle in healthcare.

Here’s what you’ll take away:

• Why most AI projects fail—and how to spot the ones that won’t.
• How to lead technical teams with vision, warmth, and accountability.
• Why proprietary data matters more than fancy algorithms.
• What real innovation feels like—and how to know when you’re missing it.

At the center of it all: a calm, fiercely smart leader who sees through the noise and builds what matters.

As she says:
“Start with the real problem. If you don’t understand the problem, AI won’t help you.”

Timestamps & Topics

📌 (01:08) Missed AI Integration Costs – “It’s faster, more effective, cheaper—but it’s not part of the core business yet.”

📌 (03:57) AI vs. Real-World Drug Impact – “The question isn’t: does it use AI? It’s: does the medicine work?”

📌 (04:48) Post-Hype AI Fallout in Pharma – “Fraud led to disillusionment. And investors paid the price.”

📌 (06:39) Corporate Blind Spots in Innovation – “It’s a danger in business to think there’s nothing to learn from others.”

📌 (09:40) Building a European AI Alliance – “At first, pharma didn’t take us seriously. That changed with the data.”

📌 (11:02) Data Ethics and Regulatory Risk – “You can massively hurt your business through accidental bias.”

📌 (13:19) Data Access for Rare Diseases – “The only solution is to make that data safely available.”

📌 (15:22) Leadership Shift: From Bayer to Startup – “It felt too obvious. I needed something riskier, more meaningful.”

📌 (21:23) Three Core Leadership Traits – “Vision. Technical understanding. And knowing when to bring in others.”

📌 (22:27) Frictionless Health Tech Adoption – “It’s inevitable. The economics—and behavior nudges—are already shaping it.”

This episode offers more than insight—it’s a playbook for building what’s next in health, tech, and leadership.

👉 Listen now, and share it with someone ready to shape the future.

🎙️ With over 200 interviews, panels, and livestreams, Beginner’s Mind ranks in the Top 10% globally—and is recognized as the leading deep tech podcast for

Send us a text

Join Christian Soschner for expert coaching.
50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now.

Support the show

Join the Podcast Newsletter: Link

Most founders add layers to gain control. Reed Hastings built an empire by removing them. 

This episode unpacks No Rules Rules—the leadership playbook behind Netflix’s rise from a DVD mail service to a global entertainment powerhouse. Co-authored by founder Reed Hastings and INSEAD professor Erin Meyer, the book reveals how to scale not through policy, but through trust, talent density, and extreme transparency. 

But this isn’t just about Netflix. 

It’s about you—if you’re building or investing in companies between Series A and IPO, where culture either compounds performance or quietly kills it. 

I walk you through 7 operational principles that deep-tech teams can apply now—lessons forged in crisis, growth, and reinvention. You’ll learn how to sunshine mistakes, pay like a pirate, and lead without becoming a bottleneck. 

Each principle is translated into coaching prompts, ready to implement this week. 

Key Takeaways: 

• Culture Outruns Capital: Don’t optimize the engine—reinvent the vehicle.
• Pro Team > Family: Loyalty is earned through excellence, not tenure.
• Candor Drives Speed: Build feedback loops that fuel progress.
• Pay Top of Market: Buy peace of mind. Unlock creative flow.
• Bet Boldly: Seek dissent. Test. Learn. Repeat.
• Context Beats Control: Share the why. Let them own the how.
• Transparency = Trust: Open up, even when it’s uncomfortable.

Timestamps:

(00:00) Intro – Why Netflix Scaled Faster by Removing Rules, Not Adding Them
(04:30) Who Is Reed Hastings? – From Math Teacher to Global Disruptor
(09:13) Book Snapshot – What Makes No Rules Rules a Real Operating System
(11:35) Lesson 1: Culture Outruns Capital – How Netflix Survived 4 Disruptions, Blockbuster Didn’t Survive One
(17:25) Lesson 2: Build a Pro Team, Not a Family – Talent Density Over Loyalty
(22:48) Lesson 3: Radical Candor = Speed – The Feedback Model That Fuels Innovation
(27:34) Lesson 4: Pay Like a Pirate – Why Netflix Pays Top of Market—No Games, Just Outcomes
(32:20) Lesson 5: Bet Bold, Fail Proudly – The 4-Step Innovation Cycle That Keeps Netflix Ahead
(39:12) Lesson 6: Lead with Context, Not Control – Scaling Leadership Without Becoming a Bottleneck
(43:28) Lesson 7: Transparency Builds Velocity – How Truth-Telling Became Netflix’s Superpower
(48:15) 7 Key Takeaways – The Culture Playbook Every Growth-Stage Founder Needs
(50:15) Personal Reflection – What I Questioned, What I’ll Steal, What Gave Me Pause
(52:00) Call to Action + What’s Next – Support the Show + Tease of the Next Episode

Why Listen:
 

• Learn how Netflix scaled without micromanagement
• Get 7 principles that push your org design, talent strategy, and leadership edge
• Discover where you're still playing defense—when your culture should be your offense
• Upgrade your leadership thinking with real examples and immediate applications

Found this useful? Like, share, and follow.
Every

Send us a text

Join Christian Soschner for expert coaching.
50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now.

Support the show

Join the Podcast Newsletter: Link

 Most cancer drugs fail. Not because the science is wrong—because we’re solving the wrong problems.

The cost? Over $2 billion per failure. And for the patient waiting on a miracle—there’s no second chance.

Behind the headlines of “precision medicine,” there’s a deeper story nobody’s telling. Until now. 

🎯 Enter Rafael Rosengarten, the scientist-turned-founder who’s rewriting the rules of drug development.

In this gripping conversation, we unpack how RNA, AI, and deep empathy could finally close the loop between biology, data, and the patient in the room. 

🎧 Watch now to explore:
1️⃣ Why drug failure isn’t a tech problem—it’s a strategy problem
2️⃣ How “information companions” will guide every medicine to the right patient
3️⃣ What pharma keeps getting wrong about biomarkers—and how to fix it
4️⃣ The untold story behind turning down a chef’s job on a Mediterranean yacht
5️⃣ The real reason Genialis may one day go out of business (and why Rafael hopes it does) 

👤 About Rafael Rosengarten
Rafael is CEO and co-founder of Genialis, the RNA biomarker company reshaping precision oncology. From academic labs to Michelin-star kitchens, his journey is anything but linear—but his mission is clear: make medicine make sense. With partners across pharma, diagnostics, and AI, Genialis is creating a world where every patient gets the treatment they actually need. 

💬 Quotes That Might Shift Your Thinking:
(00:58:37) “Our AI biomarkers de-risk clinical trials, slashing costs and saving lives.”
(01:54:46) “Every drug will have an information companion guiding it to the right patient.”
(01:14:32) “AI should free humans for empathy and creativity, not replace them.”
(00:14:13) “We now have the tools to treat every cancer as unique to each patient.”
(01:31:38) “Stop selling technology; sell solutions to real problems.” 

🧭 Timestamps to Explore:
(00:03:52) Inside the World’s Largest Medical Center
(00:10:30) How AI Is Rewiring Precision Medicine
(00:13:51) Why Precision Medicine Is Scaling Now
(00:17:34) Startups Must Solve Market Needs First
(00:23:53) Culture First, Then Business: Startup Blueprint
(00:27:57) Cancer Isn’t One Disease—It’s Thousands
(00:31:44) Predicting Drug Success with AI Biology
(00:36:40) Reimagining Biomarkers Using RNA and AI
(00:47:45) Why Early Detection Still Saves Lives
(00:57:30) Why Most Cancer Drugs Still Fail
(00:58:37) AI Biomarkers That De-Risk Clinical Trials
(01:09:42) Rethinking Dosage with Predictive Algorithms
(01:13:33) Why Human Intuition Still Matters in Science
(01:36:41) The Crystal Ball Question Pharma Can’t Ignore
(01:50:19) The moment where time disappears—and the real future begins.
(01:53:39) Every Drug Will Have an AI Companion 

🔔 Let’s Rebuild Trust in Medicine—Together
If this episode sparked a new thought—or just gave you pause—don’t let it end here.

Subscribe. Share it with someone who still believes medicine can be both scientific and deeply human.

Every action brings in minds like Rafael’s… and gets us one step closer to trea

Send us a text

Join Christian Soschner for expert coaching.
50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now.

Support the show

Join the Podcast Newsletter: Link